ArticleResearch and practice in thrombosis and haemostasis2025
Prevalence of iron deficiency in patients with mild to moderate bleeding disorders and bleeding disorder of unknown cause.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Dealing with heavy menstrual bleeding in very rare bleeding disorders: from a patient's perspective.Research and practice in thrombosis and haemostasis · 2026Article
- Bleeding assessment tools and quality of life in bleeding disorder of unknown cause.Research and practice in thrombosis and haemostasis · 2026Article
- Iron deficiency and iron deficiency anemia in inherited bleeding disorders: common, underrecognized, and undertreated.Research and practice in thrombosis and haemostasis · 2025Article
- National Bleeding Disorder Foundation Clinical Practice Recommendations for Laboratory Screening of Iron Deficiency With and Without Anemia in the Inherited Bleeding Disorders Population.Haemophilia : the official journal of the World Federation of HemophiliaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Iron deficiency (ID) and ID anemia (IDA) are often caused by chronic bleeding, especially heavy menstrual bleeding, and thus may occur at a high frequency in patients with mild to moderate bleeding disorders (MBDs). Objectives: To study the prevalence of iron deficiency in mild to moderate bleeding disorders and bleeding disorder of unknown cause. Methods: The iron status of patients with MBD from the Vienna Bleeding Biobank, a prospective cohort study, was analyzed and compared with age- and sex-matched healthy controls. ID was defined as ferritin ≤30 μg/L, transferrin saturation <16%, or iron therapy at inclusion. IDA was defined as hemoglobin <12 g/dL in women and <13 g/dL in men diagnosed with ID. Results: The rates of ID and IDA were comparable between 646 patients with MBD and 118 controls, as 250 patients with MBD (39%) had ID and 40 (6%) had IDA, compared with 37 controls with ID (31%) and 6 with IDA (5%). von Willebrand disease showed a significantly higher rate of ID than controls (49%) before correction for multiple testing, while there was no significant difference between other MBD diagnoses and controls (bleeding disorder of unknown cause: 39%; platelet function disorders: 33%; and coagulation factor deficiencies: 28%). In multivariable regression, we identified female sex, younger age, and higher body mass index, but not MBD diagnoses, bleeding score, or blood group O, associated with ID. Conclusion: ID was common among MBDs, especially von Willebrand disease and female patients, but also in controls. Our data highlight the importance of assessing iron status in patients with MBDs, especially in young female individuals, regardless of the presence of bleeding symptoms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.